Related Experiment Video

Updated: Mar 27, 2026

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.3K

MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma

Tetsu Tomonari1, Shunsaku Takeishi1, Tatsuya Taniguchi1

  • 1Department of Gastroenterology and Oncology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima City, 770-8503, Japan.

Oncotarget
|January 16, 2016
PubMed

Insights

The efflux transporter MRP3 significantly increases hepatocellular carcinoma (HCC) cell resistance to sorafenib. Knocking down MRP3 restores HCC cell sensitivity to sorafenib, identifying MRP3 as a key resistance mechanism.

Area of Science:

  • Hepatocellular Carcinoma Research
  • Cancer Drug Resistance Mechanisms
  • Molecular Biology

Background:

  • Hepatocellular carcinoma (HCC) often develops resistance to sorafenib, a standard treatment.
  • The precise mechanisms driving sorafenib resistance in HCC remain largely unknown.
  • No reliable predictive biomarkers for sorafenib treatment response in HCC have been identified.

Purpose of the Study:

  • To investigate the underlying mechanisms of sorafenib resistance in hepatocellular carcinoma (HCC) cells.
  • To establish and characterize sorafenib-resistant HCC cell lines for further study.
  • To identify potential molecular targets or biomarkers associated with sorafenib resistance.

Main Methods:

  • Established sorafenib-resistant HCC cell lines (PLC/PRF5-R1 and PLC/PRF5-R2) through continuous drug exposure.
  • Quantified drug resistance using MTT assay to determine IC50 values.
  • Analyzed protein expression of key signaling pathways (AKT, mTOR, ERK) and membrane transporters (BSEP, MDR1, MRP2, BCRP, MRP4, OCT1, MRP3) via Western blot.
  • Investigated the role of MRP3 by gene knockdown using siRNA.
  • Performed gene mutation analysis on the Raf1 kinase activation segment.

Main Results:

  • Sorafenib-resistant HCC clones exhibited significantly higher IC50 values compared to parental cells.
  • No significant alterations in AKT, mTOR, or ERK signaling pathways were observed in resistant cells.
  • Expression levels of most tested membrane transporters remained unchanged, except for a significant upregulation of MRP3 in resistant clones.
  • Knockdown of MRP3 using siRNA successfully restored sorafenib sensitivity in resistant HCC cells.
  • No mutations were found in the Raf1 kinase activation segment of resistant clones.

Conclusions:

  • The efflux transporter MRP3 plays a critical role in mediating sorafenib resistance in hepatocellular carcinoma cells.
  • Upregulation of MRP3 is a key mechanism contributing to sorafenib treatment failure in HCC.
  • MRP3 represents a potential therapeutic target for overcoming sorafenib resistance in HCC.
Keywords:
MRP3hepatocellular carcinomaresistancesorafenibtransporter

More Related Videos

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

14.5K
Methods to Study Mrp4-containing Macromolecular Complexes in the Regulation of Fibroblast Migration10:43

Methods to Study Mrp4-containing Macromolecular Complexes in the Regulation of Fibroblast Migration

Published on: May 19, 2016

7.1K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K